Study S001750

The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00766857
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 27
Start: 2009-05
Primary completion: 2012-12
Lead sponsor: Amsterdam UMC, location VUmc
Conditions: Type 2 Diabetes Mellitus; Congestive Heart Failure
Interventions: DRUG:exenatide; DRUG:Insulin glargine
Results posted: FALSE
Secondary identifiers: OTHER:EudraCT: 2008-005325-10

Registered primary outcomes

Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction). [week -2 and week 11]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014891	Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine. Chen WJY, Cardiovascular diabetology	2017	Randomized trial	PMID 28526033 DOI	cites ClinicalTrials.gov:NCT00766857; registry reference DERIVED:28526033